Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
TMB measured by NGS may ID SCLC patients who will benefit from immunotherapy
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
News
Monalizumab-cetuximab combo shows promise in advanced head and neck SCC
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or...
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
News
Early phase 2 data: Mocetinostat/durvalumab combo shows promise in mNSCLC
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression...
News
Consider treatment, testing when CLL symptoms emerge
CHICAGO – Predictive tests should be conducted before beginning therapy.
News
CLL: The initial work-up
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
News
Prognostic features could improve ALL outcomes
CHICAGO – Cytogenetic factors, minimal residual disease activity, and Philadelphia chromosome–like signature are among the features with...
News
Adding pembrolizumab to cisplatin-based CRT shows promise in HPV+ head and neck cancers
Pembrolizumab plus cisplatin-based chemoradiotherapy shows promise for locally advanced, HPV-positive head and neck squamous cell carcinoma.
News
Refractory immune-mediated colitis: Fecal transplant may be the answer
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
News
MBDA score predicts, tracks RA patients’ responses to tofacitinib and rituximab
CHICAGO – Multibiomarker disease activity score predicts RA patients’ responses to tofacitinib and tracks rituximab responses.
